Clinical management and prognosis of spinal myxopapillary ependymoma: a single-institution cohort of 72 patients.

Purpose: Myxopapillary ependymoma (MPE) was classified as grade 2 tumor in the 2021 World Health Organization central nervous system classification because of its high recurrence probability. This study aimed to investigate predictive factors and management of tumor recurrence.

Methods: Seventy-two patients with spinal MPE underwent initial surgical treatment at our hospital between 2011 and 2021.

Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.

H3 K27-altered diffuse midline glioma is a highly lethal pediatric-type tumor without efficacious treatments. Recent findings have highlighted the heterogeneity among diffuse midline gliomas with different locations and ages. Compared to tumors located in the brain stem and thalamus, the molecular and clinicopathological features of H3 K27-altered spinal cord glioma are still largely elusive, thus hindering the accurate management of patients.

YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated mA modification to activate NF-κB and promote the malignant progression of glioma.

Background: The prognosis for diffuse gliomas is very poor and the mechanism underlying their malignant progression remains unclear. Here, we aimed to elucidate the role and mechanism of the RNA N6,2'-O-dimethyladenosine (mA) reader, YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), in regulating the malignant progression of gliomas.

Methods: YTHDF2 mRNA levels and functions were assessed using several independent datasets.

Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.

Background: "Diffuse midline glioma, H3 K27M-mutant" (DMG) mainly arises within the pontine, thalamic, and spinal cord regions. Because of the rarity of spinal cord gliomas, the general knowledge surrounding DMGs is mainly based on pontine and thalamic gliomas, whereas tumor location tends to influence the clinicopathological features and prognosis.

Objective: To determine the clinicopathological characteristics and molecular profiles of DMGs located in the spinal cord.

METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma.

Understanding the role of N6-methyladenosine (mA) in tumorigenesis and stem cell maintenance is an emerging field in glioma research. However, it is necessary to study the function of mA in IDH-mutation and IDH-wildtype gliomas separately. Here, we aimed to elucidate the role and mechanism of the mA writer METTL3 in regulating the malignant progression of IDH-wildtype gliomas.